DK2120932T3 - Indazolderivater som kinasehæmmere til behandling af kræft - Google Patents
Indazolderivater som kinasehæmmere til behandling af kræftInfo
- Publication number
- DK2120932T3 DK2120932T3 DK07857632.9T DK07857632T DK2120932T3 DK 2120932 T3 DK2120932 T3 DK 2120932T3 DK 07857632 T DK07857632 T DK 07857632T DK 2120932 T3 DK2120932 T3 DK 2120932T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- treatment
- kinase inhibitors
- indazol
- derivatives
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06126701 | 2006-12-20 | ||
| PCT/EP2007/063998 WO2008074749A1 (en) | 2006-12-20 | 2007-12-14 | Indazole derivatives as kinase inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2120932T3 true DK2120932T3 (da) | 2014-10-13 |
Family
ID=39245139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07857632.9T DK2120932T3 (da) | 2006-12-20 | 2007-12-14 | Indazolderivater som kinasehæmmere til behandling af kræft |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8114865B2 (da) |
| EP (1) | EP2120932B1 (da) |
| JP (1) | JP5302896B2 (da) |
| CN (1) | CN101594862B (da) |
| AU (1) | AU2007336335B8 (da) |
| BR (1) | BRPI0720589A2 (da) |
| CA (1) | CA2673095C (da) |
| DK (1) | DK2120932T3 (da) |
| EA (1) | EA017852B1 (da) |
| ES (1) | ES2509820T3 (da) |
| MX (1) | MX2009006401A (da) |
| PL (1) | PL2120932T3 (da) |
| PT (1) | PT2120932E (da) |
| SI (1) | SI2120932T1 (da) |
| WO (1) | WO2008074749A1 (da) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| AU2008279447A1 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| EA018503B1 (ru) * | 2007-07-20 | 2013-08-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Замещенные производные индазола, активные как ингибиторы киназы |
| WO2010069966A1 (en) * | 2008-12-18 | 2010-06-24 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| JO2860B1 (en) | 2009-05-07 | 2015-03-15 | ايلي ليلي اند كومباني | Phenylendazolyl compounds |
| EP2483281B1 (en) | 2009-10-01 | 2014-06-04 | Cymabay Therapeutics, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| BR112012023021A2 (pt) * | 2010-03-16 | 2016-05-31 | Dana Farber Cancer Inst Inc | compostos de indazol e seus usos |
| WO2012075318A2 (en) * | 2010-12-01 | 2012-06-07 | Cell Signaling Technology, Inc. | Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer |
| FR2970967B1 (fr) | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
| EA023579B1 (ru) * | 2011-05-12 | 2016-06-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Замещенные производные индазола, активные в качестве ингибиторов киназы |
| JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | Ｎ−置換ヘテロシクリルカルボキサミド類 |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| ES2929759T3 (es) * | 2012-04-05 | 2022-12-01 | Nerviano Medical Sciences Srl | Nuevos agentes alquilantes |
| NZ703124A (en) * | 2012-05-23 | 2016-07-29 | Nerviano Medical Sciences Srl | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
| KR101936851B1 (ko) * | 2012-07-16 | 2019-01-11 | 한국과학기술연구원 | 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체 |
| EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| CA3139033A1 (en) | 2012-08-22 | 2014-02-27 | Cornell University | Methods for inhibiting fascin |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2015110467A1 (en) * | 2014-01-23 | 2015-07-30 | Nerviano Medical Sciences S.R.L. | Process for the preparation of substituted n-(5-benzenesulfonyl-1h-indazol-3-yl)-benzamides |
| US10231965B2 (en) * | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| WO2015127125A1 (en) | 2014-02-20 | 2015-08-27 | Cornell University | Compounds and methods for inhibiting fascin |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| CN107207471B (zh) * | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
| EP3233840B1 (en) | 2014-12-16 | 2018-11-21 | Eudendron S.r.l. | Heterocyclic derivatives modulating activity of certain protein kinases |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN104530045A (zh) * | 2015-01-14 | 2015-04-22 | 中国药科大学 | 吡唑并[4,3-c]四氢吡啶类c-Met激酶抑制剂及其制备方法和用途 |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| BR112018012255A2 (pt) | 2015-12-18 | 2018-12-04 | Ignyta Inc | método para tratar câncer |
| WO2018026890A1 (en) | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| WO2019018570A1 (en) | 2017-07-19 | 2019-01-24 | Ignyta, Inc. | PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB |
| KR102687118B1 (ko) | 2017-08-16 | 2024-07-19 | 벤더르빌트 유니버시티 | Mglur4 알로스테릭 증강제로서의 인다졸 화합물, 조성물, 및 신경 기능장애 치료 방법 |
| WO2019077506A1 (en) | 2017-10-17 | 2019-04-25 | Ignyta, Inc. | PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS |
| CN110452176A (zh) * | 2018-05-07 | 2019-11-15 | 四川大学 | 吲唑类衍生物及其制备方法和用途 |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| CN113164477A (zh) | 2018-12-14 | 2021-07-23 | 达纳-法伯癌症研究所股份有限公司 | C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF |
| EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040047869A (ko) * | 2001-09-26 | 2004-06-05 | 파마시아 이탈리아 에스.피.에이. | 키나제 억제제로서 활성인 아미노인다졸 유도체, 이의제조방법 및 이를 함유하는 약제학적 조성물 |
| FR2836915B1 (fr) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| KR101099281B1 (ko) * | 2003-03-03 | 2011-12-26 | 어레이 바이오파마 인크. | ｐ38 억제제 및 그의 사용 방법 |
| FR2871158A1 (fr) * | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| US7998974B2 (en) * | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| AR071780A1 (es) * | 2008-05-15 | 2010-07-14 | Nerviano Medical Sciences Srl | Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos |
-
2007
- 2007-12-14 WO PCT/EP2007/063998 patent/WO2008074749A1/en not_active Ceased
- 2007-12-14 PT PT78576329T patent/PT2120932E/pt unknown
- 2007-12-14 CA CA2673095A patent/CA2673095C/en not_active Expired - Fee Related
- 2007-12-14 EP EP07857632.9A patent/EP2120932B1/en active Active
- 2007-12-14 ES ES07857632.9T patent/ES2509820T3/es active Active
- 2007-12-14 US US12/520,387 patent/US8114865B2/en active Active
- 2007-12-14 JP JP2009542015A patent/JP5302896B2/ja active Active
- 2007-12-14 CN CN200780049818.0A patent/CN101594862B/zh active Active
- 2007-12-14 AU AU2007336335A patent/AU2007336335B8/en not_active Ceased
- 2007-12-14 SI SI200731506T patent/SI2120932T1/sl unknown
- 2007-12-14 MX MX2009006401A patent/MX2009006401A/es active IP Right Grant
- 2007-12-14 DK DK07857632.9T patent/DK2120932T3/da active
- 2007-12-14 PL PL07857632T patent/PL2120932T3/pl unknown
- 2007-12-14 EA EA200970595A patent/EA017852B1/ru not_active IP Right Cessation
- 2007-12-14 BR BRPI0720589-9A patent/BRPI0720589A2/pt active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009006401A (es) | 2009-06-23 |
| JP2010530840A (ja) | 2010-09-16 |
| AU2007336335A8 (en) | 2014-07-24 |
| CN101594862A (zh) | 2009-12-02 |
| AU2007336335A1 (en) | 2008-06-26 |
| EP2120932A1 (en) | 2009-11-25 |
| PT2120932E (pt) | 2014-10-10 |
| EP2120932B1 (en) | 2014-07-09 |
| WO2008074749A1 (en) | 2008-06-26 |
| CN101594862B (zh) | 2015-11-25 |
| ES2509820T3 (es) | 2014-10-20 |
| EA017852B1 (ru) | 2013-03-29 |
| US20100197665A1 (en) | 2010-08-05 |
| AU2007336335A2 (en) | 2009-08-06 |
| WO2008074749A9 (en) | 2009-05-07 |
| US8114865B2 (en) | 2012-02-14 |
| JP5302896B2 (ja) | 2013-10-02 |
| EA200970595A1 (ru) | 2010-02-26 |
| BRPI0720589A2 (pt) | 2014-02-25 |
| PL2120932T3 (pl) | 2015-02-27 |
| AU2007336335B8 (en) | 2014-07-24 |
| CA2673095A1 (en) | 2008-06-26 |
| CA2673095C (en) | 2016-03-15 |
| AU2007336335B2 (en) | 2013-05-30 |
| SI2120932T1 (sl) | 2014-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280173A (en) | Inhibitors of brutons tyrosine kinase | |
| PL2120932T3 (pl) | Indazolowe pochodne jako inhibitory kinazy do leczenia raka | |
| DK1945631T3 (da) | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer | |
| DK1981875T3 (da) | Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase | |
| CY2017012I2 (el) | Αναστολεις κινασης τυροσινης bruton | |
| CR10369A (es) | Pyrimidine derivatives as pi3k inhibitors | |
| DK2021335T3 (da) | Heterocykliske forbindelser som C-FMS-kinasehæmmere | |
| DK2220070T3 (da) | 2-benzylpyridazinonderivater som Met-kinaseinhibitorer | |
| DK2261223T3 (da) | Pyrimidinderivater anvendt som PI-3-kinasehæmmere | |
| DK2300013T4 (da) | Phosphorderivater som kinasehæmmere | |
| DK1981863T3 (da) | Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater | |
| DK2478907T3 (da) | Sammensætninger til behandling af kræft | |
| DK2848610T3 (da) | Hæmmere af kinaseaktivitet | |
| DK3483143T3 (da) | Piperidinonderivater som mdm2-inhibitorer til behandlingen af kræft | |
| EP2166846A4 (en) | JANUS KINASE INHIBITORS | |
| DK1711481T3 (da) | Fremgangsmåde til fremstilling af 2-aminothiazol-5-aromatiske carboxamider som kinaseinhibitorer | |
| DK3289876T3 (da) | Forbindelser til behandling af cancer | |
| BRPI0716981A2 (pt) | Inibidores de cinase úteis para o tratamento de doenças proliferativas | |
| EP2170073A4 (en) | SELECTIVE INHIBITORS FOR CYCLINE-RELATED KINASES | |
| EP2231143A4 (en) | JANUS KINASE INHIBITORS | |
| DE602005025733D1 (de) | Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase | |
| ATE496029T1 (de) | Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren | |
| BRPI0814628A2 (pt) | derivados ativos de indazol substituídos como inibidores da quinase | |
| DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
| DK3354650T3 (da) | Forbindelser der er nyttige som inhibitorer af ATR-kinase |